A very recent publication reported a complex combinational immunotherapic regimen consisting of four agents including a TAA-targeting antibody, IL-2, anti-PD-L1, and a potent T cell vaccine made of TAA peptide and CpG ODN, which was shown to be effective against large mouse B6 melanoma, DD-Her2/neu breast carcinoma, and TC-1 lung tumor46. The gene discussed is IL2; the disease is breast carcinoma.